Navigation Links
Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’

onal food company whose product leads are generated from medicinal plants. The Company's strategy is to develop these products through 'proof of principle' clinical testing, and then secure partners for late stage development, sales and marketing. Laboratory, manufacturing and clinical work is outsourced to selected specialists, operating under expert in-house management. This operational structure allows access to the best external research facilities whilst maintaining low fixed overheads and a lower development cost structure.


Cogane(tm)

Cogane(tm) (PYM50028) is a novel non-peptide, orally bioavailable neurotrophic factor inducer that readily crosses the blood brain barrier. In pre-clinical studies, Cogane(tm) stimulates the release of neuronal growth factors, increases neurite outgrowth and protects against neuronal degeneration. Importantly, Cogane(tm) also reverses the decrease of neuronal growth factors and reverses dopaminergic neuronal degeneration observed in vitro. When administered orally to pre-clinical models of Parkinson's disease, Cogane(tm) reverses the loss of dopaminergic neurones.

*Movement Disorders (2007) Vol 22 (Suppl 16): page S18, abstract number 58.

Parkinson's disease

Parkinson's disease is a movement disorder characterised by muscle rigidity, tremor, a slowing of physical movement (bradykinesia) and, in extreme cases, a loss of physical movement (akinesia). The primary symptoms are the result of altered signaling of an area of the brain, the striatum, responsible for the control of movement. This is caused by degeneration of dopaminergic neurones between the striatum and the substantia nigra part of the brain leading to insufficient formation and action of dopamine. Parkinson's disease is therefore termed a neurodegenerative disease. The disease is slow in onset and the appearance of symptoms reflects the gradual loss of dopaminergic neurones.


The prevalence of the disease is estimat
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:2/27/2015)... 27, 2015 Report Details   ... you trends, R&D progress, and predicted revenues ,Where is ... are the commercial prospects for this market and related ... and other trends to 2025, discussing data, opportunities and ... assess regenerative medicine : cell-based therapies that aim ...
(Date:2/27/2015)... Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... fourth quarter and full year ended December 31, 2014. ... PTC. We are now a growing commercial-stage biopharma company, ... rare disease space," stated Stuart W. Peltz, Ph.D., Chief ... bring the first treatment for Duchenne muscular dystrophy to ...
(Date:2/27/2015)... -- Bionik Laboratories Corp. (OTC:DWTPD), a Delaware ... Bionik Laboratories, Inc., a Toronto ... accredited investors of units consisting of its common stock ... million. Shares of the Company,s common stock will continue ... symbol "DWTPD" until FINRA,s approval of the ticker "BNKL." ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
... Fla., Dec. 9, 2011  Breckenridge Pharmaceutical, Inc. ... final approval for their Abbreviated New Drug Application (ANDA) ... are AB rated to Pamine®, a prescription medicine that ... peptic ulcers. Pamine® is marketed by Kenwood Therapeutics. The ...
...  Thoratec (NASDAQ: THOR), a world leader in device-based mechanical ... hearts, said today it will be participating in the ... December 13. Taylor C. Harris, Senior Director ... update on the company, beginning at 10:15 a.m., Eastern ...
Cached Medicine Technology:
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax accounting ... consulting services in addition to a variety of other ... planning. Company finances are a complicated matter that should ... this, complex Canadian tax laws can make it even ... Mew and Company works to advise their clients on ...
(Date:2/28/2015)... Indosoft Inc , developers of ... are pleased to announce the development of Q-Suite 5.9. ... versions of Q-Suite, this new version will include enhancements ... new features to the leading edge call center software. ... will add features to enhance security and protection. Administrators ...
(Date:2/28/2015)... For those people who are unable to ... Applied Research Foundation (Meso Foundation) will broadcast its ... at 9:30 AM. , The live broadcast is free ... be accessed through any browser on a computer or ... is a unique event that covers important treatment information ...
(Date:2/28/2015)... Pioneer Millworks reclaimed USA wood will be on ... Show, an annual, premier sustainable building event in Tokyo, ... manufacturers of the latest building products, services and technology. ... manufactured by Pioneer Millworks from their Oregon and New ... hotels, retailers, and corporate offices. Nichibi Global , ...
(Date:2/28/2015)... Pismo Beach, CA (PRWEB) February 28, 2015 ... the needs of Central Coast area residents, recently announced ... Whitening System. It’s a treatment option for new ... patients kick off 2015 with a bright, white smile, ... the discounted price of $299, marked down from the ...
Breaking Medicine News(10 mins):Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2
... Oct. 2 - Flatulence isn,t much fun,for the person having it - or those nearby. ... For,example:, -- Slow down your eating: A little ... everything you swallow. To reduce the amount of air, eat and ... -- Avoid airy drinks and foods: Air also gets into ...
... Patients who undergo liver transplantation at age 60 ... similar to those of younger patients and they ... published in a new study in the October ... John Wiley & Sons. The article is also ...
... John Cousins,President of Biomoda, Inc. (OTC Bulletin Board: ... before the,New Mexico State Legislature,s Interim Tobacco Settlement ... for funding a clinical,study using the company,s assay ... Mexico legislature last year appropriated $350,000 to fund ...
... N.Y., Oct. 2 Suzanne Somers, New York,Times ... Long Island,s most,brilliant, wellness oriented doctors will share ... Expo (Nutrition, Aesthetics, Vitality,Efficacy, Life ... NAVEL ... ... weight loss, beauty, fitness, longevity, vitality and,lifetime wellness. ...
... President to Sign the Bill, CHICAGO, Oct. ... the approval by both congressional chambers of the ... many beneficial dental provisions. The bill now heads ... care, especially for children, is one of the ...
... would ... health IT system, CLEVELAND, Oct. 2 Sidney Taurel, ... LLY ), in a speech,today at the Cleveland Clinic, called ... actively collaborate on a health,information technology system that would provide ...
Cached Medicine News:Health News:Fighting the Gassy Effects of Good Eating, From the Harvard Health Letter 2Health News:Patients over age 60 do well after liver transplantation 2Health News:Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer 2Health News:Healthy Weight Loss Begins With What You Permit to Enter Your Mind, More So Than Even Your Mouth! 2Health News:AGD Applauds Congressional Support of SCHIP Reauthorization 2Health News:Lilly's CEO Calls for Reform of Nation's Drug Safety System 2Health News:Lilly's CEO Calls for Reform of Nation's Drug Safety System 3
... scotopic sensitivity (threshold) testing provides clinically ... of ophthalmic conditions. Dark adaptometry is ... of retinal degenerations, senile miosis, high ... blinding conditions, while whole-field scotopic sensitivity ...
... Inc.s EPIC-4000 offers fast and easy ERG, ... compact, modular package. It provides ERG stimulus ... the International Standard for the Clinical Electrophysiology ... including the pattern ERG, allow a variety ...
... 3 will enable eye care professionals to ... improved ultrasound technology. The PACHETT 3 uses ... used in all the DGH pachymeters used ... Model 555 PACHETTE 3 is capable of ...
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
Medicine Products: